PRKDC and neoplasm: In addition, pyridostatin triggers a type I innate immune response in the cells lacking BRCA1/2, which may potentiate its anti‐tumoral activity; (v) pyridostatin combination with the DNA‐PKcs inhibitor NU‐7441 and paclitaxel shows long‐term efficacy against BRCA1‐deficient tumours.